Nevertheless, tumors lacking PD-L1 expression on cancer cells still respond to anti-PD-L1 therapy, indicating that the expression of PD-L1 on cancer cells and tumor-infiltrating immune cells might prevent an antitumor CD8+ T cell response [11–13]. Here, CD8A is linked to cancer.